US 12,134,613 B2
Method for the manufacture of 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof
Andrew Roy Turner, Macclesfield (GB); Andrew Timothy Turner, Macclesfield (GB); Gareth Paul Howell, Macclesfield (GB); Malcolm Allan Young Gall, Cambridge (GB); Keith Raymond Mulholland, Cambridge (GB); Neil Keith Adlington, Cambridge (GB); Zhenping Tian, Shandong (CN); Bo Liu, Shanghai (CN); Qisun Gong, Shanghai (CN); and Wei Yu, Shanghai (CN)
Assigned to AstraZeneca AB, Sodertalje (SE); and Hutchison Medipharma Limited, Shanghai (CN)
Appl. No. 17/274,820
Filed by AstraZeneca AB, Sodertalje (SE); and Hutchison Medipharma Limited, Shanghai (CN)
PCT Filed Sep. 10, 2019, PCT No. PCT/EP2019/074083
§ 371(c)(1), (2) Date Mar. 10, 2021,
PCT Pub. No. WO2020/053198, PCT Pub. Date Mar. 19, 2020.
Claims priority of application No. PCT/CN2018/104941 (WO), filed on Sep. 11, 2018.
Prior Publication US 2022/0048904 A1, Feb. 17, 2022
Int. Cl. C07D 471/04 (2006.01)
CPC C07D 471/04 (2013.01) 13 Claims
OG exemplary drawing
 
1. A process for the preparation of Savolinitib (I)

OG Complex Work Unit Chemistry
comprising the preparation of (1S)-1-imidazo[1,2-a]pyridin-6-ylethanamine (III),

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, comprising the steps of (i) asymmetric enzymatic transamination of 1-imidazo[1,2-a]pyridin-6-ylethanone (II),

OG Complex Work Unit Chemistry
in the presence of an amine transaminase, pyridoxal phosphate, and an amine source; and (ii) isolation of (1S)-1-imidazo[1,2-a]pyridin-6-ylethanamine (III), or a pharmaceutically acceptable salt thereof.